The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Introduction Microalbuminuria and hypertension are risk factors for the development of diabetic nephropathy. Blockade of the renin-angiotensin system reduces progression to diabetic nephropathy in type 1 diabetic patients, whereas similar data are lacking for hypertensive type 2 diabetic subjects. We evaluated the renoprotective effect of an angiotensin II receptor antagonist, irbesartan, in hypertensive type 2 diabetic patients with microalbuminuria. Material and methods Five hundred and ninety hypertensive type 2 diabetic patients with microalbuminuria were enrolled in this multinational, randomised, double-blind, placebo-controlled study of irbesartan 150 mg/daily or 300 mg/daily or matching placebo for two years. The primary outcome was time to progression to diabetic nephropathy, defined as a persistent overnight albuminuria > 200 micrograms/min and at least a 30 per cent increase from baseline. Results Baseline characteristics in the three groups were similar. Ten patients (5.2 per cent) receiving irbesartan 300 mg and 19 patients (9.7 per cent) receiving irbesartan 150 mg daily reached the primary end point, as compared to 30 (14.9 per cent) patients on placebo (hazard ratio 0.30 [95 per cent confidence interval 0.14 to 0.61], p Discussions Irbesartan is renoprotective independently of its blood pressure lowering effect in type 2 diabetic subjects with microalbuminuria. It is safe and well tolerated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Antihypertensive therapy reduces the risk of albuminuria (67)(68)(69)(70), and among people with type 1 or 2 diabetes with established CKD (eGFR <60 mL/min/1.73m 2 and UACR $300 mg/g creatinine), ACE inhibitor or ARB therapy reduces the risk of progression to ESKD (71)(72)(73)(74)(75)(76)(77)(78)(79)(80).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [77]
In the citing paper
“In the setting of lower levels of albuminuria (30-299 mg/g creatinine), ACE inhibitor or ARB therapy at maximum tolerated doses in trials has reduced progression to more advanced albuminuria ($300 mg/g creatinine), slowed CKD progression, and reduced cardiovascular events but has not reduced progression to ESKD (74,77).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [77]
In the citing paper
“The IRMA-2 study showed that treatment with irbesartan, an ARB, was associated with a dose-dependent reduction in the risk of progression of CKD, with an almost 3-fold risk reduction with the highest dose (300 mg per day) at 2 years of followup.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [11]
In the citing paper
“This effect was independent of the blood pressure -lowering properties of irbesartan.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [11]
In the citing paper
“In this regard, it should be noted that in related studies in patients with type 1 and type 2 diabetes, 1,28,29 the benefits of captopril or irbesartan were not tested in the presence of concurrent calcium-channel-antagonist therapy.”
From Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (2001) · cites this paper as [29]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Pitt, B., Poole-Wilson, P. A., Segal, R., Martinez, F. A., Dickstein, K., Camm, A. J., Konstam, M. A., Riegger, G., Klinger, G. H., Neaton, J., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02213-3 · Cited by 1,961
The Effect of Age on Creatinine Clearance in Men: A Cross-sectional and Longitudinal Study
Rowe, J. W., Andres, R., Tobin, J. D., Norris, A. H., & Shock, N. W. (1976) · Journal of Gerontology · doi:10.1093/geronj/31.2.155 · Cited by 1,104
Gæde, P., Vedel, P., Parving, H.-H., & Pedersen, O. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07368-1 · Cited by 981
Self-citationTatti, P., Pahor, M., Byington, R. P., Mauro, P. D., Guarisco, R., Strollo, G., & Strollo, F. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.597 · Cited by 850
Ravid, M., Savin, H., Jutrin, I., Bental, T., Katz, B., & Lishner, M. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-8-199304150-00001 · Cited by 775
Research works printed but not linked: 9
- Parving H-H, Østerby R, Ritz E. Diabetic nephropathy. In: Brenner BM, ed. The kidney. 6th ed. Philadelphia: W.B. Saunders, 2000:1731-73.
- Hofman W, 1989, Lab Med, 13, 470
- Seelig HP, 1969, Z Klin Chem Klin Biochem, 7, 581
- Goldstein DE, 1986, Clin Chem, 32, B64
- 10.1001/jama.271.4.275 · doi:10.1001/jama.271.4.275 · Paper page
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Mantel N, 1959, J Natl Cancer Inst, 27, 719
- Agardh C-D, 1996, J Hum Hypertens, 10, 185
- Estacio RO, 2000, Diabetes Care, 23, B54
Cited by
Items 701–800 of 1,008
Cagnoni, F., Njwe, C. A. N., Zaninelli, A., Ricci, A., Daffra, D., D’Ospina, A., Preti, P., & Destro, M. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s11816 · Cited by 49
MicroRNAs and their delivery in diabetic fibrosis
Wonnacott, A., Denby, L., Coward, R. J., Fraser, D. J., & Bowen, T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114045 · Cited by 45
Polkinghorne, K. R., Su, Q., Chadban, S. J., Shaw, J. E., Zimmet, P., & Atkins, R. C. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.12.034 · Cited by 43
Liu, I.-M., Tzeng, T., Liou, S., & Chang, C. J. (2011) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/140103 · Cited by 43
“Urinary albumin excretion has been demonstrated to be a good clinical predictor of renal lesions in diabetic nephropathy [22, 23].”
BackgroundSuzuki, H., Kanno, Y., Kaneko, K., Kaneko, M., Kotaki, S., Mimura, T., & Takane, H. (2004) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1526-0968.2004.00142.x · Cited by 43
Toblli, J. E., DeRosa, G., Cao, G., Piorno, P., & Pagano, P. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00661.x · Cited by 43
Blood pressure lowering and renin-angiotensin system blockade
Unger, T. (2003) · Journal of Hypertension · doi:10.1097/00004872-200307006-00002 · Cited by 43
Baltatzi, M. S., Savopoulos, C., & Hatzitolios, A. I. (2011) · Europe PMC (PubMed Central) · Cited by 64
Gagliardini, E., Perico, N., Rizzo, P., Buelli, S., Longaretti, L., Perico, L., Tomasoni, S., Zoja, C., Macconi, D., Morigi, M., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.03.025 · Cited by 43
Schievink, B., de Zeeuw, D., Parving, H., Rossing, P. R., & Heerspink, H. J. L. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12655 · Cited by 45
“The detailed design, rationale, and study outcome for these trials have been previously published [12-14].”
BackgroundSelf-citationGlobal diabetic kidney disease research from 2000 to 2017
Zou, L., & Sun, L. (2019) · Medicine · doi:10.1097/md.0000000000014394 · Cited by 42
Landelijke Transmurale Afspraak Chronische nierschade
(2009) · Huisarts en Wetenschap · doi:10.1007/bf03085802 · Cited by 42
Péchère-Bertschi, A., Greminger, P., Hess, L., Philippé, J., & Ferrari, P. (2005) · Blood Pressure · doi:10.1080/08037050500340018 · Cited by 42
Levin, A., & Stevens, L. A. (2005) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.11.005 · Cited by 44
Agelis, G., Resvani, A., Durdağı, S., Spyridaki, K., Tůmová, T. (., Slaninová, J., Giannopoulos, P., Vlahakos, D., Liapakis, G., Mavromoustakos, T., et al. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.07.040 · Cited by 42
on behalf of the FinnDiane Study Group, Sigfrids, F. J., Forsblom, C. M., Harjutsalo, V., Thorn, L. M., Wadén, J., Elonen, N., Ahola, A. J., Saraheimo, M., & Groop, P. (2018) · Diabetologia · doi:10.1007/s00125-018-4564-8 · Cited by 47
Preoperative assessment of elderly cancer patients
Pasetto, L. M., Lise, M., & Monfardini, S. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.08.001 · Cited by 47
Probucol delays progression of diabetic nephropathy
Endo, K., Miyashita, Y., Sasaki, H., Ohira, M., Saiki, A., Koide, N., Otsuka, M., Oyama, T., Murano, T., Ito, Y., et al. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.05.012 · Cited by 41
Böhm, M., Thoenes, M., Neuberger, H., Gräber, S., Reil, J., Bramlage, P., & Volpe, M. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp124 · Cited by 42
Piskorz, D. L. (2020) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-020-00361-6 · Cited by 47
The Forgotten Antiproteinuric Properties of Diuretics
Trujillo, H., Caravaca‐Fontán, F., Caro, J., Morales, E., & Praga, M. (2021) · American Journal of Nephrology · doi:10.1159/000517020 · Cited by 44
Optimal Antagonism of the Renin-Angiotensin-Aldosterone System: Do We Need Dual or Triple Therapy?
Werner, C. M., Pöss, J., & Böhm, M. (2010) · Drugs · doi:10.2165/11537910-000000000-00000 · Cited by 51
Endothelial dysfunction and hypertension in diabetes mellitus
Dandona, P., Chaudhuri, A., & Aljada, A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.006 · Cited by 42
Meredith, P. (2005) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200505030-00004 · Cited by 45
The renin-angiotensin system in blacks: Active, passive, or what?
Price, D. A., & Fisher, N. D. L. (2003) · Current Hypertension Reports · doi:10.1007/s11906-003-0025-x · Cited by 43
Boronat, M., García-Cantón, C., Quevedo, V., Lorenzo-Villegas, D. L., López-Ríos, L., Batista, F., Riaño, M., Saavedra, P., & Checa, M. D. (2013) · Renal Failure · doi:10.3109/0886022x.2013.835266 · Cited by 42
The Nephrotic Syndrome is an immunoinflammatory disorder
Camici, M. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.04.072 · Cited by 44
Erythromycin ameliorates renal injury via anti-inflammatory effects in experimental diabetic rats
Tone, A., Shikata, K., Sasaki, M., Ohga, S., Yozai, K., Nishishita, S., Usui, H., Nagase, R., Ogawa, D., Okada, S., et al. (2005) · Diabetologia · doi:10.1007/s00125-005-1945-6 · Cited by 31
The Role of Angiotensin II Type 1 Receptor Antagonists in Elderly Patients with Hypertension
Thomas, G. N., Chan, P., & Tomlinson, B. (2006) · Drugs & Aging · doi:10.2165/00002512-200623020-00004 · Cited by 47
Hypertension in people with Type 2 diabetes: knowledge‐based diabetes‐specific guidelines
Working Party of the International Diabetes Federation (European Region) (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.01021.x · Cited by 44
Zaltzman, J. S., Nash, M. M., Chiu, R., & Prasad, R. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg593 · Cited by 41
Mizuno, M., Sada, T., Kato, M., Fukushima, Y., Terashima, H., & Koike, H. (2006) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000245241.79959.d6 · Cited by 40
Management of Blood Pressure in Patients With Diabetes
Grossman, E., & Messerli, F. H. (2011) · American Journal of Hypertension · doi:10.1038/ajh.2011.77 · Cited by 40
Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents
Gnudi, L., & Karalliedde, J. J. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv093 · Cited by 43
“Large clinical studies, such as Microvascular Heart Outcomes Prevention Evaluation (Micro-HOPE), Reduction in ENdpoints with the Angiotensin Antagonist Losartan, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria, Irbesartan Diabetic Nephropathy Trial and BENEDICT have demonstrated that RAAS blockade is…”
BackgroundKidney disease in the elderly: update on recent literature
Campbell, K. H., & O’Hare, A. M. (2008) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3282f5dd90 · Cited by 45
Antidiabetic Effects ofCorni FructusExtract in Streptozotocin-Induced Diabetic Rats
Gao, D., Li, Q., Gao, Z., & Wang, L. (2012) · Yonsei Medical Journal · doi:10.3349/ymj.2012.53.4.691 · Cited by 40
Vitamin D improves diabetic nephropathy in rats by inhibiting renin and relieving oxidative stress
Deng, X., Cheng, J., & Shen, M. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0414-4 · Cited by 45
“The incidence of DN in diabetic patients whose urine albumin excretion rate is 20–200 μg/min is 10 to 20-fold higher than that in diabetic patients with normal albuminuria [7].”
BackgroundProgression, Remission and Regression of Chronic Renal Diseases
Cortinovis, M., Ruggenenti, P. L., & Remuzzi, G. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000445844 · Cited by 42
Jie, L., Pengcheng, Q., He, Q., Linlin, B., Meng, Z., Wang, F., Min, J., Li, Y., Zhang, Y., Yang, Q., et al. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.06.024 · Cited by 41
Park, H. Y., Schumock, G. T., Pickard, A. S., & Akhras, K. S. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.15.1611.31962 · Cited by 40
Farmer, A. A., Stevens, R., Hirst, J. A., Lung, T. W.-C., Oke, J. L., Clarke, P., Glasziou, P., Neil, A., Dunger, D. B., Colhoun, H. M., et al. (2014) · Health Technology Assessment · doi:10.3310/hta18140 · Cited by 44
Krämer, S., Loof, T., Martini, S., Rückert, M., Wang, Y., Böhler, T., Shimizu, F., Kawachi, H., Neumayer, H., & Peters, H. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00442.2004 · Cited by 40
Diabetic Kidney Disease in Elderly Individuals
Williams, M. E. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.10.011 · Cited by 43
Controlling hypertension in patients with diabetes.
Konzem, S. L., Devore, V. S., & Bauer, D. W. (2002) · PubMed · Cited by 46
Pentoxifylline: A potential therapy for chronic kidney disease
Lin, S., Chen, Y., Chiang, W., Tsai, T., & Wy, C. (2004) · Nephrology · doi:10.1111/j.1440-1797.2004.00267.x · Cited by 40
Renal damage associated with proteinuria
Praga, M., & Morales, E. (2002) · Kidney International · doi:10.1046/j.1523-1755.62.s82.9.x · Cited by 44
SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review
Thomas, M. C., Neuen, B. L., Twigg, S. M., Cooper, M. E., & Badve, S. V. (2023) · Endocrine Connections · doi:10.1530/ec-23-0005 · Cited by 51
Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors?
Wiggins, K. J., & Kelly, D. J. (2009) · Kidney International · doi:10.1038/ki.2009.105 · Cited by 39
Roles of the (pro)renin receptor in the kidney
Ôshima, Y., Morimoto, S., & Ichihara, A. (2014) · World Journal of Nephrology · doi:10.5527/wjn.v3.i4.302 · Cited by 43
Composite renal endpoints: was ACCOMPLISH accomplished?
Heerspink, H. L., & de Zeeuw, D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60098-0 · Cited by 39
Urine RAS components in mice and people with type 1 diabetes and chronic kidney disease
Wysocki, J. A., Goodling, A., Burgaya, M., Whitlock, K. B., RUZINSKI, J. T., BATLLE, D. C., & Afkarian, M. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00074.2017 · Cited by 43
“RAS activation is generally accepted as an important mechanism of DKD progression (3, 27, 39).”
BackgroundRipley, E. B. D. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.04.008 · Cited by 37
Treatment of Microalbuminuria in Patients with Type 2 Diabetes Mellitus
Jerums, G., & MacIsaac, R. J. (2002) · Treatments in Endocrinology · doi:10.2165/00024677-200201030-00004 · Cited by 47
Fluorescein-labeled sinistrin as marker of glomerular filtration rate
Pill, J., Kraenzlin, B., Jander, J., Sattelkau, T., Sadick, M., Klötzer, H.-M., Deus, C., Kraemer, U., & Gretz, N. (2005) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2005.03.020 · Cited by 38
Ruilope, L. M., & Segura, J. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)90091-9 · Cited by 42
Clinical importance of microalbuminuria in diabetes and hypertension
Bakris, G. L. (2004) · Current Hypertension Reports · doi:10.1007/s11906-004-0053-1 · Cited by 40
B7–1 Is Not Induced in Podocytes of Human and Experimental Diabetic Nephropathy
Gagliardini, E., Novelli, R., Corna, D., Zoja, C., Ruggiero, B., Benigni, A., & Remuzzi, G. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015030266 · Cited by 39
Imai, E., Ito, S., Haneda, M., Chan, J. C. N., & Makino, H. (2006) · Hypertension Research · doi:10.1291/hypres.29.703 · Cited by 41
Adjuvant strategies for prevention of glomerulosclerosis
McCarty, M. F. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2004.11.048 · Cited by 40
Protein Glycation in Diabetes as Determined by Mass Spectrometry
Lapolla, A., Molin, L., & Traldi, P. (2013) · International Journal of Endocrinology · doi:10.1155/2013/412103 · Cited by 40
Koïtka, A., Cao, Z., Koh, P., Watson, A. M. D., Sourris, K. C., Loufrani, L., Soro‐Paavonen, A., Walther, T., Woollard, K. J., Jandeleit-Dahm, K. A. M., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1619-x · Cited by 41
Vejakama, P., Ingsathit, A., McKay, G. J., Maxwell, A. P., McEvoy, M., Attia, J. R., & Thakkinstian, A. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0753-9 · Cited by 43
Hypertension in Minority Populations: New Guidelines and Emerging Concepts
Rodríguez, F., & Ferdinand, K. C. (2015) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.08.004 · Cited by 39
Diabetes after Kidney Donation
Ibrahim, H. N., Kukla, A., Cordner, G., Bailey, R., Gillingham, K. J., & Matas, A. J. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02944.x · Cited by 40
Shlomai, G., Grassi, G. M., Grossman, E., & Mancia, G. (2013) · Journal of Clinical Hypertension · doi:10.1111/jch.12185 · Cited by 46
“dependent significant decrease of UAE compared with placebo but only a trend towards less frequent nonfatal CV events.(22) A post hoc analysis of the Reduction in Endpoint in Noninsulin-Dependent Diabetes Mell-”
ResultParikh, C. R., Fischer, M. J., Estacio, R. O., & Schrier, R. W. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh300 · Cited by 38
Preventing end stage renal disease in diabetic patients — genetic aspect (part I)
Jacobsen, P. K. (2005) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2005.001 · Cited by 39
Kusunoki, H., Taniyama, Y., Rakugi, H., & Morishita, R. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000103 · Cited by 38
Fisher, M. (2004) · Heart · doi:10.1136/hrt.2003.018622 · Cited by 41
Identification and Management of Diabetic Nephropathy in the Diabetes Clinic
Craig, K. J., Donovan, K., Munnery, M., Owens, D. R., Williams, J. D., & Phillips, A. O. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1806 · Cited by 38
The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics
The BENEDICT Group (2003) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00028-x · Cited by 40
The vasopeptidase inhibitor AVE7688 ameliorates Type 2 diabetic nephropathy
Sch�fer, S. G., Linz, W., Vollert, H., Biemer‐Daub, G., R�tten, H., Bleich, M., & Busch, A. E. (2004) · Diabetologia · doi:10.1007/s00125-003-1264-8 · Cited by 38
Niacin-ER and Lovastatin Treatment of Hypercholesterolemia and Mixed Dyslipidemia
Yim, B. T., & Chong, P. H. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c161 · Cited by 18
Chen, Y., Liu, P., Chen, X., Li, Y., Zhang, F., & Wang, Y. (2018) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2018.01.017 · Cited by 35
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 85
Liu, Y., Gao, G., Yang, C., Zhou, K., Shen, B., Liang, H., & Jiang, X. (2014) · International Journal of Endocrinology · doi:10.1155/2014/393109 · Cited by 36
Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes
Pena, M. J., de Zeeuw, D., Mischak, H., Jankowski, J., Oberbauer, R. W., Woloszczuk, W., Benner, J., Dallmann, G., Mayer, B., Mayer, G. J., et al. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv252 · Cited by 42
Mancia, G., Dominiczak, A. F., Fagard, R. H., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., Schmieder, R. E., Vahanian, A. S., Camm, A. J., Dean, V., et al. (2007) · Cited by 50
Remonti, L. R., Dias, S., Leitão, C. B., Kramer, C. K., Klassmann, L. P., Welton, N. J., Ades, A. E., & Gross, J. L. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.04.020 · Cited by 38
Long-term impact of bariatric surgery in diabetic nephropathy
Young, L. H., Hanipah, Z. N., Brethauer, S. A., Schauer, P. R., & Aminian, A. (2018) · Surgical Endoscopy · doi:10.1007/s00464-018-6458-8 · Cited by 37
Proteinuria and Microalbuminuria in Adults: Significance, Evaluation, and Treatment
Venkat, K. K. (2004) · Southern Medical Journal · doi:10.1097/01.smj.0000140833.51533.46 · Cited by 42
Xu, J., Lee, E. T., Devereux, R. B., Umans, J. G., Bella, J. N., Shara, N. M., Yeh, J. L., Fabsitz, R. R., & Howard, B. V. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.11.010 · Cited by 38
Early detection and management of the high-risk patient with elevated blood pressure
de la Sierra, A. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s930 · Cited by 43
Renal complications of diabetes
Min, T., Stephens, M. W., Kumar, P. R. G., & Chudleigh, R. A. (2012) · British Medical Bulletin · doi:10.1093/bmb/lds030 · Cited by 47
Blood Pressure Control, Drug Therapy, and Kidney Disease
Contreras, G., Greene, T., Agodoa, L. Y., Cheek, D., Junco, G., Dowie, D., Lash, J., Lipkowitz, M., Miller, E. R., Ojo, A., et al. (2005) · Hypertension · doi:10.1161/01.hyp.0000166746.04472.60 · Cited by 37
Additive protection by LDR and FGF21 treatment against diabetic nephropathy in type 2 diabetes model
Shao, M., Yu, L., Zhang, F., Lu, X., Li, X., Cheng, P., Lin, X., He, L., Jin, S., Tan, Y., et al. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00026.2015 · Cited by 37
“DIABETIC NEPHROPATHY (DN) is a severe complication of diabetes and the leading cause of end-stage renal disease (38).”
BackgroundThe need for optimal and coordinated management of CKD
Levin, A. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.09902.x · Cited by 45
Efficacy of Angiotensin Receptor Blockers in Cardiovascular Disease
Maggioni, A. P. (2006) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-006-9799-9 · Cited by 38
Capítulo 3 - Avaliação Clínica e Complementar
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Figueiredo, C., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160153 · Cited by 51
Microalbuminuria predicts overt proteinuria among patients with HIV infection
Szczech, L. A., Menezes, P., Quinlivan, E. B., van der Horst, C., Ja, B., & Svetkey, L. (2010) · HIV Medicine · doi:10.1111/j.1468-1293.2009.00805.x · Cited by 41
Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice
Dong, Y., Liu, L., Lai, Z.-F., Yamamoto, E., Kataoka, K., Nakamura, T., Fukuda, M., Tokutomi, Y., Nako, H., Ogawa, H., et al. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e328338bb11 · Cited by 38
Improving Microvascular Outcomes in Patients with Diabetes through Management of Hypertension
McGill, J. B. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.03.1980 · Cited by 37
Zheng, N., Lin, X., Wen, Q., Kintoko, Zhang, S., Huang, J., Xu, X., & Huang, R. (2013) · Toxicology Letters · doi:10.1016/j.toxlet.2013.03.001 · Cited by 36
RetractedZhang, N., Zhuang, M., Ma, A., Wang, G., Cheng, P., Yang, Y., Wang, X., Zhang, J., Chen, X., & Lü, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083059 · Cited by 34
“Microalbuminuria was defined as UAE between 20 and 200 mg/min or between 30 and 300 mg/ 24 h, macroalbuminuria was defined as above 200 mg/min or 300 mg/24 h in at least two of three consecutive 24-h urine collections [8,13,14].”
BackgroundFukuda, M., Yamanaka, T., Mizuno, M., Miura, T., Tomonari, T., Kato, Y., Ichikawa, T., Miyagi, S., Shirasawa, Y., Ito, A., et al. (2011) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00167.2011 · Cited by 36
Renal protection in diabetes: lessons from ONTARGET®
Ritz, E., Schmieder, R. E., & Pollock, C. A. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-60 · Cited by 40
Potassium Handling with Dual Renin-Angiotensin System Inhibition in Diabetic Nephropathy
Buren, P. N. V., ADAMS-HUET, B. A., Nguyen, M., Molina, C., & Toto, R. D. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07460713 · Cited by 38
Combined Angiotensin Receptor Modulation in the Management of Cardio-Metabolic Disorders
Paulis, L., Foulquier, S., Namsolleck, P., Recarti, C., Steckelings, U. M., & Unger, T. (2015) · Drugs · doi:10.1007/s40265-015-0509-4 · Cited by 39
MiR‐802 causes nephropathy by suppressing NF‐κB‐repressing factor in obese mice and human
Sun, D., Chen, J., Wu, W., Tang, J., Luo, L., Zhang, K., Jin, L., Lin, S., Gao, Y., Yan, X., et al. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14193 · Cited by 35
Conservative management for patients with chronic kidney disease refusing dialysis
Castro, M. C. M. (2018) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2018-0028 · Cited by 69
Metadata
- Authors
- Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P.
- Affiliations
- Steno Diabetes Center Copenhagen (DK)
- University Hospital Magdeburg (DE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-09-20
- Volume
- 345
- Issue
- 12
- Pages
- 870-878
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2003670762
- Semantic Scholar
- bec1f00c2120232a55a25b7d846d63e92a3ff8fc
- Cited by
- 2,873
- References
- 26
- Citations by year
- 2026: 30 · 2025: 44 · 2024: 50 · 2023: 61 · 2022: 61 · 2021: 58 · 2020: 63 · 2019: 50 · 2018: 63 · 2017: 71 · 2016: 84 · 2015: 88 · 2014: 105 · 2013: 103 · 2012: 117
- FWCI
- 146.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- irbesartan, diabetic nephropathy, type 2 diabetes, hypertension, microalbuminuria, renal protection, angiotensin receptor blockers, renin-angiotensin system blockade, albuminuria, blood pressure, dose comparison, adverse events, renin-angiotensin system inhibitors
- MeSH terms
- Irbesartan, Adult, Aged, Albuminuria, Antihypertensive Agents, Biphenyl Compounds, Creatinine, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Humans, Hypertension, Male, Middle Aged, Tetrazoles, Proportional Hazards Models, Disease Progression, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.